213
Participants
Start Date
August 31, 2009
Primary Completion Date
October 31, 2012
Study Completion Date
February 29, 2016
axitinib
axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
axitinib
axitinib 5mg BID (open-label) + placebo dose titration (blinded)
axitinib
axitinib 5mg BID (open-label)
University of Maryland Greenebaum Cancer Center, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Johns Hopkins Hospital, Baltimore
Hospital de La Princesa, Madrid
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario La Paz, Madrid
Medizinische Hochschule Hannover, Abt. Haematologie, Haemostaseologie & Onkologie, Hanover
H. Lee Moffitt Cancer Center and Research Institute, Tampa
Universitaetsklinikum Duesseldorf, Düsseldorf
The Ohio State University, James Cancer Hospital, Columbus
JamesCare in Kenny, Columbus
Cleveland Clinic, Cleveland
West Chester Hospital Medical Building, West Chester
The University Hospital, Cincinnati
University of Cincinnati, Cincinnati
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Investigational Drug Services, IUHSCC, Indianapolis
IU Health University Hospital, Indianapolis
Cancer and Hematology Centers of Western Michigan, Grand Rapids
Klinikum der J. W. Goethe-Universitaet, Medizinische Klinik II, Frankfurt
Washington University, St Louis
Nebraska Methodist Hospital, Omaha
Eberhardt-Karls-Universitaet Tuebingen, Klinik fuer Urologie, Tübingen
Texas Oncology, Sammons Cancer Center, Dallas
Nevada Cancer Institute, Las Vegas
Klinikum Weiden Klinik fuer Urologie, Andrologie und Kinderurologie, Weiden
Comprehensive Blood and Cancer Center, Bakersfield
Bay Area Cancer Research Group, LLC, Pleasant Hill
Diablo Valley Oncology and Hematology Medical Group Inc, Pleasant Hill
East Bay Medical Oncology/Hematology Medical Associates Inc, Pleasant Hill
East Bay Medical Oncology/Hematology Medical Associates Inc., Antioch
East Bay Medical Oncology/Hematology Medical Associates Inc, San Leandro
Oregon Health and Science University, Portland
Virginia Mason Medical Center, Seattle
"FSBSI N.N. Blokhin Russian Cancer Research Center", Moscow
"FSBIRussian Scientific Center of Roengenoradiology of the MH of RF", Moscow
"State Healthcare Institution Leningrad Regional Oncology Dispensary", Poselok Kuzmolovskiy
Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint Petersburg
Saint-Petersburg's State Healthcare Institution 'City Clinical Oncology Dispensary', Saint Petersburg
Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk
"GBUZ Samara Regional Clinical Oncology Dispensary", Samara
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Barnes-Jewish Hospital, St Louis
University of Nebraska Medical Center, Omaha
The University of Texas MD Anderson Cancer Center, Houston
Masarykuv onkologicky ustav, Brno
Fakultni nemocnice Olomouc Onkologicka klinika, Olomouc
Fakultni nemocnice Na Bulovce, Prague
Krajska zdravotni, a.s. - Masarykova nemocnice V Usti nad Labem, o.z., Ústí nad Labem
Nagoya University Hospital, Nagoya
Sapporo Medical University Hospital, Sapporo
Hokkaido University Hospital, Sapporo
Kobe University Hospital, Kobe
Kinki University Hospital, Sayama
Hamamatsu University School of Medicine, University Hospital, Hamamatsu
National Cancer Center, Chuo-ku
Japanese Foundation For Cancer Research Cancer Institute Hospital, Koto-ku
Keio University Hospital, Shinjuku-ku
Akita University Hospital, Akita
Chiba Cancer Center, Chiba
Kyushu University Hospital, Fukuoka
Nagasaki University Hospital, Nagasaki
Tokushima University Hospital, Tokushima
Yamagata University Hospital, Yamagata
Lead Sponsor
Pfizer
INDUSTRY